Enteric microbial marker for ulcerative colitis, application of intestinal microbial marker and ulcerative colitis detection model

By identifying specific intestinal microbial markers of ulcerative colitis and constructing a random forest model, the problem of insufficient accuracy of existing diagnostic technology is solved, and more accurate diagnosis and personalized treatment of ulcerative colitis are achieved.

CN119360942APending Publication Date: 2025-01-24QIANJI (XIAN) BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411471635.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-21
Publication Date
2025-01-24

AI Technical Summary

Technical Problem

The existing diagnostic techniques for ulcerative colitis have problems such as insufficient accuracy, dependence on invasive examinations and high subjectivity, making it difficult to provide specific, sensitive and easy-to-detection biomarkers.

Method used

Provides a kind of ulcerative colitis intestinal microbial logo, including specific bacteria, such as bacteria and monocylogenic bacteria. It is constructed through high -throughput sequencing and random forest models to detect the diagnosis and diagnosis of ulcerative colitis and treat.

Benefits of technology

It improves the diagnostic accuracy of ulcerative colitis, reduces the reliance on invasive examinations, and can tailor a personalized treatment plan for each patient, improving treatment effects and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119360942A_ABST
    Figure CN119360942A_ABST
Patent Text Reader

Abstract

The invention provides an ulcerative colitis intestinal microbial marker, application thereof and an ulcerative colitis detection model, and belongs to the technical field of biology and biological medicine. By analyzing the composition of the intestinal microbe markers of the ulcerative colitis patient and monitoring the change of the intestinal microbe markers of the patient, the method can guide the adjustment of the intestinal microecology of the ulcerative colitis patient, makes a personalized treatment scheme for each UC patient, recovers the normal flora of the intestinal tract of the ulcerative colitis patient, and improves the treatment effect of the ulcerative colitis. The treatment effect is improved. The ulcerative colitis detection model can more accurately identify the intestinal flora difference between ulcerative colitis patients and healthy people, the ROC curve of the ulcerative colitis detection model is close to the upper left corner, the ulcerative colitis detection model has a high true positive rate under each threshold value, the AUC value reaches 0.8106, and the ulcerative colitis detection model can be used for detecting the ulcerative colitis. The ulcerative colitis detection model has good performance when distinguishing positive and negative samples.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biology and biomedicine technology, and in particular to an ulcerative colitis intestinal microbial marker and application thereof and an ulcerative colitis detection model. Background Art

[0002] Ulcerative colitis (UC) is a chronic inflammatory bowel disease with the main symptoms of recurrent abdominal pain, diarrhea, and bloody stools. The incidence of UC is increasing worldwide, seriously affecting the quality of life of patients. In addition, patients with long-term UC have long-term inflammatory stimulation of the intestinal mucosa, which increases the risk of colon cancer.

[0003] Currently, the diagnostic techniques for ulcerative colitis include clinical evaluation, endoscopy, imaging, laboratory tests and other methods. Among them, although endoscopy has high accuracy, it is an invasive operation and will bring certain discomfort and risks to patients. In addition, the results of endoscopic and pathological examinations are affected by the experience and skills of the operator and interpreter, and there is a certain degree of subjectivity. Although imaging and laboratory tests can provide useful information, the sensitivity and specificity of these methods are usually lower than those of endoscopy and cannot be used as independent diagnostic tools.

[0004] For UC patients, accurate diagnosis and effective treatment are the key to alleviating symptoms, improving quality of life, and reducing life restrictions. Therefore, in order to improve the accuracy of UC diagnosis, it is crucial to find more specific, sensitive and easy-to-detect biomarkers for existing UC diagnostic technologies and reduce reliance on invasive examinations for UC examination and treatment. Summary of the invention

[0005] The purpose of the present invention is to provide an ulcerative colitis intestinal microbial marker and its application and an ulcerative colitis detection model, which can customize a personalized treatment plan according to the specific situation of the patient, thereby improving the treatment effect and quality of life.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides an intestinal microbial marker for ulcerative colitis, characterized in that the microbial marker comprises the following bacterial species: Eubacterium recale, Bacteroides uniformis, Odoribacter splanchnicus, Bacteroides ovatus, Bifidobacterium bifidum, Bacteroides vulgatus, Alistipes shahii, Ruminococcus torques, Eubacterium eligens, Alistipes putredinis, and Bacteroides faecis CAG 32.

[0008] The present invention also provides an application of an ulcerative colitis intestinal microbial marker in the preparation of a drug for treating ulcerative colitis.

[0009] The present invention also provides an application of an intestinal microbial marker for ulcerative colitis, the application including a product for preparing a diagnosis of whether a patient suffers from ulcerative colitis or is at risk of suffering from ulcerative colitis, a target for disease assessment and treatment of ulcerative colitis, and a construction of an ulcerative colitis detection model; the product includes any one of a detection reagent, a detection kit, and a detection chip.

[0010] The present invention also provides a method for constructing an ulcerative colitis detection model, comprising the following steps:

[0011] (1) Total DNA was extracted from the feces of patients with ulcerative colitis and healthy people, and high-throughput sequencing was performed after pretreatment. The sequencing results were annotated with species and analyzed for composition, gene abundance, function annotation, and difference analysis;

[0012] (2) Using random forest to screen intestinal microbial markers of ulcerative colitis, constructing a random forest model, optimizing parameters, and training and testing the constructed random forest model with a training set and a test set to obtain an ulcerative colitis detection model;

[0013] (3) The metagenome and abundance information of the patient to be tested are input into the ulcerative colitis detection model for identification.

[0014] Furthermore, in step (1), the species annotation and composition spectrum analysis includes:

[0015] Alpha diversity analysis, beta diversity analysis, bacterial community sample composition, sample heatmap, and species interaction network analysis.

[0016] Furthermore, in step (1), the gene abundance analysis includes gene Core-Pan curve, gene dilution curve, and correlation analysis between samples of gene numbers.

[0017] Furthermore, in step (1), the functional annotation includes: KEGG data rate functional annotation analysis, HUMAnN3, KO functional abundance and analysis, Module functional abundance and analysis, Pathway functional abundance and analysis.

[0018] Furthermore, in step (1), the difference analysis includes: Lefse analysis, dominant species difference, multivariate analysis of variance, and rank sum test difference.

[0019] Furthermore, in step (2), the parameters for optimizing the parameters are determined according to GridSearchCV.

[0020] The beneficial effects of the present invention compared with the prior art are:

[0021] (1) The present invention provides intestinal microbial markers for detecting ulcerative colitis. By analyzing the composition of intestinal microbial markers of patients with ulcerative colitis and monitoring changes in the intestinal microbial markers of patients, the present invention can guide the adjustment of the intestinal microecology of patients with ulcerative colitis, tailor a personalized treatment plan for each UC patient, restore the normal intestinal flora of patients with ulcerative colitis, and improve the treatment effect.

[0022] (2) The present invention extracts biomarkers related to the pathogenesis of ulcerative colitis from metagenomic data, uses a random forest algorithm to construct a prediction model, uses a random forest algorithm to construct a random forest model, and trains and tests the constructed random forest model with a training set and a test set to obtain an ulcerative colitis detection model. The ulcerative colitis detection model of the present invention can more accurately identify the differences in intestinal flora between ulcerative colitis (UC) patients and healthy people. The ROC curve of the ulcerative colitis detection model of the present invention is close to the upper left corner, and has a high true positive rate at each threshold, and the AUC value reaches 0.8106, indicating that the ulcerative colitis detection model of the present invention performs well in distinguishing positive and negative samples.

[0023] (3) The ulcerative colitis detection model of the present invention can realize the early diagnosis of ulcerative colitis, avoid unnecessary medical examinations and treatment procedures, and help patients save medical costs. In addition, the ulcerative colitis detection model of the present invention can continuously monitor the changes in intestinal microbial markers, combining microbiome and machine learning, which can not only evaluate the treatment effect, but also flexibly adjust the treatment plan according to the actual situation, providing patients with a new prognostic assessment tool, further enhancing the understanding of UC, and promoting the widespread application of microbiome in the field of clinical medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0025] Figure 1 This is a flow chart for constructing the ulcerative colitis detection model in Example 1;

[0026] Figure 2 This is a graph showing the results of ten cross-validation runs in Example 1;

[0027] Figure 3 It is the "Mean DecreaseAccuracy" indicator in the random forest model of Example 1;

[0028] Figure 4 is the ROC curve in Example 1;

[0029] Figure 5 This is the judgment standard for the ulcerative colitis detection model in Example 1. DETAILED DESCRIPTION

[0030] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0031] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0032] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0033] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0034] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0035] The present invention provides a method for constructing an ulcerative colitis detection model, which specifically comprises the following steps:

[0036] (1) Total DNA was extracted from the feces of patients with ulcerative colitis and healthy people, and high-throughput sequencing was performed after pretreatment. The sequencing results were annotated with species and analyzed for composition, gene abundance, function annotation, and difference analysis;

[0037] The species annotation and composition spectrum analysis include:

[0038] Alpha diversity: Shannon, Simpson, Insimpson index analysis;

[0039] beta diversity: Bray-CurtisPCoa / PCA / NMDS / UPGMA analysis;

[0040] Bacteria sample composition, sample heatmap;

[0041] Species interaction network analysis.

[0042] The gene abundance analysis includes gene Core-Pan curve, gene dilution curve, and correlation analysis between samples of gene numbers.

[0043] The functional annotations include: KEGG data rate functional annotation analysis, HUMAnN3: quantitative pathway abundance, KO functional abundance and analysis, Module functional abundance and analysis, Pathway functional abundance and analysis.

[0044] The difference analysis includes: Lefse analysis, dominant species difference, multivariate variance adonis, MaAsLin, and rank sum test difference.

[0045] (2) Using random forest to screen intestinal microbial markers of ulcerative colitis, constructing a random forest model, optimizing parameters, and training and testing the constructed random forest model with a training set and a test set to obtain an ulcerative colitis detection model;

[0046] Among them, the screened microbial markers include the following species: Eubacterium recale, Bacteroides uniformis, Odoribacter-splanchnicus, Bacteroides ovatus, Bifidobacterium bifidum, Bacteroides vulgatus, Alistipes shahii, Ruminococcus torques, Eubacterium eligens, Alistipes putredinis, and Bacteroides faecis CAG 32.

[0047] (3) The metagenome and abundance information of the patient to be tested are input into the ulcerative colitis detection model for identification.

[0048] Example 1

[0049] Embodiment 1 of the present invention provides a method for constructing an ulcerative colitis detection model, which specifically comprises the following steps:

[0050] (1) Extraction of fecal DNA: Fecal samples from 322 patients with ulcerative colitis and 107 healthy controls were collected using a stool collection kit, and fecal DNA was extracted using the MagBeads Fecal Genomic Kit. Take 300 mg of fecal sample and 1000 μL Pre-Wash Buffer, vortex until the sample is completely uniform; centrifuge the sample at 14000 rpm for 5 minutes, discard the supernatant, add 980 μL Lysis Buffer F1, 10 μL RNase A Solution and 120 μL Lysis Buffer F2 to the LysingMatrix E tube, and vortex for 10 minutes; centrifuge at 14000 rpm / min for 5 minutes to separate particle fragments; transfer 900 μL supernatant to a 2.0 mL microcentrifuge tube, add 250 μL PPS, and mix by inverting 20 times; centrifuge at 14000 rpm for 5 minutes, transfer 1000 μL supernatant to a new 2.0 mL microcentrifuge tube, and then add 1000 μL Binding Buffer F and 10 μL Magnetic Beads were vortexed to mix; the test tube was placed on a magnetic rack for 3 minutes to allow the magnetic beads to settle, and then the supernatant was discarded; 1000 μL Wash Buffer F1 was added to the test tube, and the beads were shaken on a shaker for 3 minutes, and the test tube was placed on a magnetic rack for 1 minute to allow the magnetic beads to settle, and then the supernatant was discarded; 1000 μL Wash Buffer F2 was added to the test tube, and the beads were shaken on a shaker for 3 minutes, and the test tube was placed on a magnetic rack for 1 minute, and then the supernatant was discarded; the operation was repeated and washed again with Wash Buffer F2; then the magnetic beads were air-dried at 55°C; 100 μL TE Buffer was added and incubated at 55°C for 5 minutes; the test tube was placed on a magnetic rack until the magnetic beads were precipitated, and the supernatant (eluted DNA) was transferred to a clean 1.5 mL microcentrifuge tube and stored at -20°C for a long time.

[0051] (2) Construction of ulcerative colitis detection model

[0052] Use an ultrasonic disruptor to randomly break high molecular weight DNA into fragments of about 300 bp, repair the ends of the fragmented DNA to make them blunt ends; connect specific adapter sequences to both ends of the repaired DNA fragments, and remove excess adapters, primers and other impurities through magnetic beads or column purification; use specific primers to PCR amplify the DNA fragments with adapters to enrich a sufficient amount of library fragments; use fastp software to perform quality control on the sequencing data, including removing adapters and low-quality sequences; use Bowtie2 to filter out reads that may come from the host, and then use the Illumina platform for high-throughput sequencing. The sequencing results are sorted according to Figure 1The species annotation and composition spectrum analysis, gene abundance analysis, functional annotation, and differential analysis processes were analyzed, and the results were input into the random forest model. Random forest was used to screen the intestinal microbial markers of ulcerative colitis, and a random forest model was constructed. The biomarkers of 12 bacterial genera that changed significantly between patients with ulcerative colitis and healthy people were found: Eubacterium recale, Bacteroides uniformis, Odoribacter splanchnicus, Bacteroides ovatus, Bifidobacterium bifidum, Bacteroides vulgatus, Alistipes shahii, Ruminococcus torques, Eubacterium eligens, Alistipes putredinis, and Bacteroides faecis CAG_32.

[0053] Using the training set of ulcerative colitis patients and healthy people, the python software sklearn.Ensemble.RandomForestClassifier module was used to train the random forest model on the training set to obtain the random forest detection model; the stability and reliability of the random forest model were verified by ten-fold cross validation, and the python software GridSearchCV module was used to search for the best parameters. The random forest model was constructed using the best parameters, and the ulcerative colitis detection model was obtained by training and testing with the training set and test set. The results are shown in Figure 2. Figure 2 As shown in Table 1.

[0054] Figure 2 The vertical axis reflects the value of the cross-validation error, which ranges roughly from 0.10 to 0.40. There are several curves in the line chart, which represent different variable selection methods. The black curve clearly shows the trend of the cross-validation error as the number of variables increases. This curve initially shows a downward trend, indicating that the prediction error of the model is gradually decreasing in the process of adding variables. Both the model training set and the test set have high accuracy, indicating that the model results are good. The retention performance of 12 bacterial genera is the best.

[0055] Table 1 Random forest model indicators

[0056]

[0057] In Table 1, "Mean DecreaseAccuracy" and "Mean Decrease Gini" are two important indicators in the random forest model. "Mean DecreaseAccuracy" indicates the degree of reduction in the prediction accuracy of the random forest. The larger the value, the greater the importance of the variable. "Mean Decrease Gini" calculates the impact of each variable on the heterogeneity of the observed values ​​at each node of the classification tree, thereby comparing the importance of the variable. The larger the value, the greater the importance of the variable (see the results). Figure 3 ).

[0058] The horizontal axis (X-axis) of the ROC curve represents 1-Specificity, that is, the false positive rate, which ranges from 0 to 1, reflecting the proportion of negative examples that the model mistakenly predicts as positive examples. The vertical axis (Y-axis) represents Sensitivity, that is, the true positive rate, which measures the ability of the model to correctly identify positive examples. The results are shown in Figure 4 .

[0059] Figure 4 In the figure, the solid red line clearly depicts the ROC curve of the model, while the shaded part represents the confidence interval (CI). The ROC curve of the present invention is close to the upper left corner, and has a higher true positive rate at each threshold. The area under the curve (AUC) is close to 1, indicating that the classification performance of the model is better. The AUC value of the present invention reaches 0.8106, indicating that the classifier performs well in distinguishing positive and negative samples. The CI ranges from 0.7823 to 0.8388, which provides a reliable evaluation of the AUC value, indicating the stability of the model performance.

[0060] The metagenome and abundance information of the patient to be tested are input into the ulcerative colitis detection model, and the patient is judged whether he or she is ill according to the predicted score. The judgment criteria are: risk value 0-0.5, low risk; 0.5-0.7 medium risk; 0.7-1 high risk. The results are shown in Figure 5 .

[0061] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A intestinal microbial marker for ulcerative colitis, characterized in that: The intestinal microbial markers include the following species: Eubacterium recale, Bacteroides uniformis, Odoribacter-splanchnicus, Bacteroides ovatus, Bifidobacterium bifidum, Bacteroides vulgatus, Alistipes shahii, Ruminococcus torques, Eubacterium eligens, Alistipes putredinis, and Bacteroides faecis CAG 32.

2. Use of the intestinal microbial marker for ulcerative colitis according to claim 1 in the preparation of a drug for treating ulcerative colitis.

3. A use of the intestinal microbial marker for ulcerative colitis according to claim 1, characterized in that: The application includes the preparation of products for diagnosing whether a patient has ulcerative colitis or is at risk of ulcerative colitis, using them as targets for disease assessment and treatment of ulcerative colitis, and constructing ulcerative colitis detection models; the product includes any one of a detection reagent, a detection kit, and a detection chip.

4. A method for constructing an ulcerative colitis detection model, characterized in that: The steps include: (1) Total DNA was extracted from the feces of patients with ulcerative colitis and healthy people, and high-throughput sequencing was performed after pretreatment. The sequencing results were annotated with species and analyzed for composition, gene abundance, function annotation, and difference analysis; (2) Use random forest to screen intestinal microbial markers of ulcerative colitis, construct a random forest model, optimize parameters, and train and test the constructed random forest model using training sets and test sets to obtain an ulcerative colitis detection model; (3) The metagenome and abundance information of the patient to be tested are input into the ulcerative colitis detection model for identification.

5. The method for constructing an ulcerative colitis detection model according to claim 4, characterized in that: In step (1), the species annotation and composition spectrum analysis includes: Alpha diversity analysis, beta diversity analysis, bacterial community sample composition, sample heatmap, and species interaction network analysis.

6. The method for constructing an ulcerative colitis detection model according to claim 4, characterized in that: In step (1), the gene abundance analysis includes gene Core-Pan curve, gene dilution curve, and correlation analysis between gene numbers in samples.

7. The method for constructing an ulcerative colitis detection model according to claim 4, characterized in that: In step (1), the functional annotation includes: KEGG data rate functional annotation analysis, HUMAnN3, KO functional abundance and analysis, Module functional abundance and analysis, Pathway functional abundance and analysis.

8. The method for constructing an ulcerative colitis detection model according to claim 4, characterized in that: In step (1), the difference analysis includes: Lefse analysis, dominant species difference, multivariate analysis of variance, and rank sum test difference.

9. The method for constructing an ulcerative colitis detection model according to claim 4, characterized in that: In step (2), the parameters for optimizing the parameters are determined according to GridSearchCV.